{"id":56471,"date":"2023-05-03T00:04:24","date_gmt":"2023-05-02T22:04:24","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/"},"modified":"2023-05-03T00:04:24","modified_gmt":"2023-05-02T22:04:24","slug":"scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/","title":{"rendered":"Scribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting"},"content":{"rendered":"
\n

\nData on Scribe\u2019s X-Editor technologies validates the high activity, specificity and deliverability achievable through CRISPR by Design\u2122<\/i><\/p>\n

<\/a><\/p>\n

ALAMEDA, Calif.–(BUSINESS WIRE)–#CRISPR<\/a>–Scribe Therapeutics Inc., a molecular engineering company creating genetic medicines through its CRISPR by Design\u2122 approach to genetic modification, today announced a presentation on its X-Editor (XE) technology at the 26th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place in Los Angeles, Calif. and virtually from May 16-20, 2023.<\/p>\n

\nScribe\u2019s suite of XE genome editing tools are comprehensively engineered from natural CRISPR-Cas enzymes to exhibit increased activity, specificity and deliverability. The company\u2019s presentation will include data demonstrating the potential of the company\u2019s platform and CRISPR by Design\u2122 approach to overcome challenges with efficacy and safety that existing technologies face.<\/p>\n

\nOral Presentation Title<\/b>: Comprehensive Engineering of CasX Holoenzyme to Create an X-Editor with High Activity, Specificity and Deliverability
\n
Abstract Number<\/b>: 262
\n
Session Title<\/b>: Genome & Epigenome Editing Technologies I
\n
Date<\/b>: Friday, May 19, 2023
\n
Time<\/b>: 5:15 – 5:30 p.m. PT
\n
Location<\/b>: Concourse Hall 152 & 153, Los Angeles Convention Center, Los Angeles, CA
\n
Speaker<\/b>: Addison Wright, Ph.D., Principal Scientist at Scribe<\/p>\n

\nAbout Scribe Therapeutics<\/b><\/p>\n

\nScribe Therapeutics is a molecular engineering company focused on creating best-in-class in vivo<\/i> therapies that permanently treat the underlying cause of disease. Founded by CRISPR inventors and leading molecular engineers Benjamin Oakes, Brett Staahl, David Savage, and Jennifer Doudna, Scribe engineers bacterial immune systems into genetic medicines through its CRISPR by Design\u2122 approach leveraging all previous iterations of CRISPR technology. The company is backed by leading individual and institutional investors including Andreessen Horowitz, Avoro Ventures and Avoro Capital Advisors, OrbiMed Advisors, Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, Inc., funds managed by Wellington Management, RA Capital Management, and Menlo Ventures. To learn more about Scribe\u2019s mission to engineer the future of genetic medicine, visit www.scribetx.com<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nThermal for Scribe Therapeutics
\n
media@scribetx.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Data on Scribe\u2019s X-Editor technologies validates the high activity, specificity and deliverability achievable through CRISPR by Design\u2122 ALAMEDA, Calif.–(BUSINESS WIRE)–#CRISPR–Scribe Therapeutics Inc., a molecular engineering company creating genetic medicines through its CRISPR by Design\u2122 approach to genetic modification, today announced a presentation on its X-Editor (XE) technology at the 26th American Society of Gene & … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-56471","6":"format-standard","7":"category-industry"},"yoast_head":"\nScribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Scribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Data on Scribe\u2019s X-Editor technologies validates the high activity, specificity and deliverability achievable through CRISPR by Design\u2122 ALAMEDA, Calif.–(BUSINESS WIRE)–#CRISPR–Scribe Therapeutics Inc., a molecular engineering company creating genetic medicines through its CRISPR by Design\u2122 approach to genetic modification, today announced a presentation on its X-Editor (XE) technology at the 26th American Society of Gene & ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-02T22:04:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230502006186\/en\/1633762\/21\/Scribe_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Scribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting\",\"datePublished\":\"2023-05-02T22:04:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\\\/\"},\"wordCount\":334,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230502006186\\\/en\\\/1633762\\\/21\\\/Scribe_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\\\/\",\"name\":\"Scribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230502006186\\\/en\\\/1633762\\\/21\\\/Scribe_Logo.jpg\",\"datePublished\":\"2023-05-02T22:04:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230502006186\\\/en\\\/1633762\\\/21\\\/Scribe_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230502006186\\\/en\\\/1633762\\\/21\\\/Scribe_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Scribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Scribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Scribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - Pharma Trend","og_description":"Data on Scribe\u2019s X-Editor technologies validates the high activity, specificity and deliverability achievable through CRISPR by Design\u2122 ALAMEDA, Calif.–(BUSINESS WIRE)–#CRISPR–Scribe Therapeutics Inc., a molecular engineering company creating genetic medicines through its CRISPR by Design\u2122 approach to genetic modification, today announced a presentation on its X-Editor (XE) technology at the 26th American Society of Gene & ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2023-05-02T22:04:24+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230502006186\/en\/1633762\/21\/Scribe_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Scribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting","datePublished":"2023-05-02T22:04:24+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/"},"wordCount":334,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230502006186\/en\/1633762\/21\/Scribe_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/","url":"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/","name":"Scribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230502006186\/en\/1633762\/21\/Scribe_Logo.jpg","datePublished":"2023-05-02T22:04:24+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230502006186\/en\/1633762\/21\/Scribe_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230502006186\/en\/1633762\/21\/Scribe_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-announces-oral-presentation-at-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Scribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56471","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=56471"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56471\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=56471"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=56471"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=56471"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}